Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$117.99
+1.7%
$142.77
$64.85
$212.75
$25.14B0.893.27 million shs6.73 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$50.42
-5.4%
$51.73
$22.28
$59.55
$21.14B1.058.09 million shs7.48 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.22
-0.6%
$28.38
$10.58
$30.33
$21.03B1.145.19 million shs5.67 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$50.17
+2.0%
$46.48
$27.07
$51.63
$5.89B0.71.30 million shs1.69 million shs
The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
+1.72%-13.93%-21.93%-19.28%+79.56%
Moderna, Inc. stock logo
MRNA
Moderna
-5.35%+3.34%-0.51%+25.70%+97.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-0.58%+1.39%+0.93%+9.23%+171.56%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+1.99%+6.39%+1.31%+7.52%+59.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$117.99
+1.7%
$142.77
$64.85
$212.75
$25.14B0.893.27 million shs6.73 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$50.42
-5.4%
$51.73
$22.28
$59.55
$21.14B1.058.09 million shs7.48 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.22
-0.6%
$28.38
$10.58
$30.33
$21.03B1.145.19 million shs5.67 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$50.17
+2.0%
$46.48
$27.07
$51.63
$5.89B0.71.30 million shs1.69 million shs
The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
+1.72%-13.93%-21.93%-19.28%+79.56%
Moderna, Inc. stock logo
MRNA
Moderna
-5.35%+3.34%-0.51%+25.70%+97.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-0.58%+1.39%+0.93%+9.23%+171.56%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+1.99%+6.39%+1.31%+7.52%+59.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$210.9578.79% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-29.13% Downside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$30.554.55% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.17
Buy$56.0011.62% Upside

Current Analyst Ratings Breakdown

Latest SRRK, INSM, MRNA, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Insmed, Inc. stock logo
INSM
Insmed
Set Price Target$185.00
5/8/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Reiterated RatingSell (D)
5/8/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy
5/8/2026
Insmed, Inc. stock logo
INSM
Insmed
Lower Price TargetBuy$230.00 ➝ $226.00
5/8/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Boost Price TargetOverweight$53.00 ➝ $55.00
5/8/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Boost Price TargetBuy$58.00 ➝ $65.00
5/8/2026
Insmed, Inc. stock logo
INSM
Insmed
Lower Price TargetOutperform$220.00 ➝ $205.00
5/8/2026
Insmed, Inc. stock logo
INSM
Insmed
Lower Price TargetOverweight$177.00 ➝ $160.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Insmed, Inc. stock logo
INSM
Insmed
$606.42M42.17N/AN/A$3.25 per share36.30
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B10.29N/AN/A$18.67 per share2.70
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M719.89N/AN/A$7.45 per share3.92
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$2.30 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$5.75N/A134.08N/A-144.44%-130.11%-51.57%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$1.17N/AN/AN/A-6,079.94%-19.04%-18.15%5/20/2026 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%N/A

Latest SRRK, INSM, MRNA, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2026Q4 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.26N/AN/AN/A$3.41 millionN/A
5/7/2026Q1 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million
5/7/2026Q1 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
3/3/2026Q4 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.86-$0.76+$0.10-$0.76N/AN/A
2/19/2026Q4 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.07-$1.54-$0.47-$1.54$263.97 million$263.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Insmed, Inc. stock logo
INSM
Insmed
0.80
4.47
4.10
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
30.66
30.66
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.71
8.64
6.95

Institutional Ownership

CompanyInstitutional Ownership
Insmed, Inc. stock logo
INSM
Insmed
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664216.75 million212.20 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860715.70 million638.41 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
140119.83 million103.89 millionOptionable

Recent News About These Companies

HC Wainwright Predicts Stronger Earnings for Scholar Rock
Scholar Rock (SRRK) Q1 2026 Earnings Transcript
Scholar Rock Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Insmed stock logo

Insmed NASDAQ:INSM

$117.99 +1.99 (+1.72%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$118.20 +0.22 (+0.18%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Moderna stock logo

Moderna NASDAQ:MRNA

$50.42 -2.85 (-5.35%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$49.92 -0.50 (-0.98%)
As of 07:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$29.22 -0.17 (-0.58%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$29.38 +0.16 (+0.53%)
As of 07:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$50.17 +0.98 (+1.99%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$50.21 +0.04 (+0.07%)
As of 07:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.